Monday’s ESMO 2022 update brings news of arobust Keytruda/Padcev combination，positive data from Regeneron regarding Libtayo in cutaneous squamous cell carcinoma（CSCC），雨水保护系统和管道保护系统 GRAIL。
Amgen's Lumakras and Vectibix Effective Against CRC
数据源 Amgen's Phase Ib CodeBreaK101study showed Lumakras（sotorasib），along with Vectibix（panitumumumab），is安全和effective入口，入口KRASG12C-mutated colorectal cancer（CRC），the company announced
Vectibix is Amgen's monoclonal anti-epidermal growth factor receptor（anti-EGFR）antibody。The objective response rate（ORR）in the trial was 30%，which is significant，as David M.Reese，M.D.，executive vice president of Research and Development at Amgen，stated that for this patient population，treatment response rates can be as low as2%。
The data was presented during an oral session on on Monday at the European Society for Medical Oncology（ESMO）Annual Meeting in Paris，France。
As a result of this positive data，Reese said Amgen will“continue to focus on combination approaches in colorectal cancer，including advancing CodeBreaK 300，the Phase III LUMAKRAS plus Vectibix trial in the chemotherapy-refractory patient population.”
Astellas，Seagen and Merck Score in Urothelial Cancer
Astellas and Seagen’s Padcev（enfortumab vedotin-ejfv）in combination with电枢，电枢sKeytruda in metastatic urothelial cancer（Ia/mUC）demonstrated a64.5%confirmed objective response rate（ORR），the companies reported Monday。
The Phase Ib/II trial cohort Kmet the primary endpoint.Of the participants assessed，10.5%achieved a complete response and 53.9%demonstrated a partial response.The median duration of response（DOR）per BICR was not reached。
In amonotherapy arm assessing Padcev monotherapy as first-line treatment for the same indication，data demonstrated a45.2%confirmed ORR.The monotherapy arm was not designed to be compared to the combination arm。
Jonathan E.Rosenberg，M.D.，chief of genitourinary medical oncology service，division of solid tumoroncology at Memorial Sloan Kettering and Cohort K primary investigator，support the ongoing investigation of enfortumab vedotin and pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.”
Libtayo Combo Appears Promising in Neoadjuvant CSCC
Among16presentations at ESMO，再热，再热 announcedpositive clinical data from a combination therapy of Libtayo（cemiplimab）asneoadjuvant monotherapy in stage II to IV resectable CSCC。
The data，from the primary analysis of a confirmatory Phase II trial，was also published in the新建England Journal of Medicine。
In the Phase II trial，79patients received up to four fixed doses of Libtayo every three weeks before surgery.62received all four doses and 70underwent surgery.Ofthese participants，63.3%had a combined pathologic response rate， with50.6%achieving the primary endpoint of complete pathologic response and 12.7%demonstrating a major pathologic response by independent pathologic review。
There was a68%objective response rate（ORR）with5complete responses and 49 partial responses per local imaging review。
“This is exactly what our broad pipeline is trying to do，”using a variety of approaches to turn“cold tumors”into“hot tumors，”David Weinreich，.D.，EVP，global clinical development at Regeneron，said in a Monday webcast。
GRAIL’s Galleri More than Doubles Cancers Detected
GRAIL’s Galleri multi-cancer early detection（MCED）screening blood test added to standard of care screening预应力混凝土 the number of cancers detected compared to standard screening alone，the company announced Monday。
GRAIL’s Galleri assay“detected more cancers than all U.S.Preventive Services Task Force-recommended standard single cancer screenings combined，”Jeffrey Venstrom，.D.，chief medical officer at GRAIL，said in a statement.These included Stage I cancers of the liver，small intestine and uterus，and Stage II pancreatic，bone and oropharyngeal cancers。
“This is is particularly notable given the PATHFINDER population was heavily screened with higher-than-average rates for mammography，colonoscopy and low-dose CT lung scans，“Venstrom added。
“We are far more likely to have a cancer we aren’t being screened for with standard single screening tests，源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源于源，“Josh Ofman，president at GRAIL，told BioSpace。”We are very pleased with the PATHFINDER results。Adding GRAIL's multi-cancer early detection test to standard-of-care screening more than doubled the number of cancers diagnosed in the population studied compared with standard screening alone.In fact，71%of the participants whose cancers were found with our MCED test were diagnoswith cancers that dot not haroutine
Jiangsu Hengrui Reports“Significantly Prolonged OS”in uHCC
Jiangsu Hengrui Pharmaceuticals Co.reported that camrelizumab，an anti-PD1checkpoint inhibitor，combined with rivoceranib（apatinib），受保护的操作系统and progression-free survival（PFS），with improved ORR versus sorafenib in first-line unresectable hepatocellular carcinoma（uHCC）。
Median OS was22.1months compared to 15.2months with sorafenib alone.The median PFS for the combination was5.6months compared to 3.7 months for standard of care sorafenib.And confirmed ORR for the combination was25.4%compared to 5.9%for sorafenib。
Lyell Presents Trial Design FOR CAR T-cell Therapy
Lyell Immunopharma announceda poster of its first-in-human Phase I trial design for LYL797.The drug is an ROR1-targeted CAR T-cell therapy for the treatment of solid tumors.It is specifically targeting patients with receptor tyrosine kinase-like orphan receptor1-positive（ROR1+）solid tumors。
LYL797uses both Gen-R and Epi-R，Lyell’s novel reprogramming technologies engineered to overcome barriers to successful adoptive cell therapy，such as T-cell exhaustion and lack of durable stemness.Thetrial will evaluate the drug in patients with relapsed/refractory triple-netive breast ll lung cancer（NSCLC）。
“We look forward to testing our technology platforms in the clinic，可伸缩性和可伸缩性刚度as barriers to successful cell therapy in solid tumors，“Tina Albertson，.D.，Ph.D.，Lyell’s chief medical officer，toldBioSpace。
